Kastelein JJ, et al. Circulation 2008;117:3002-9 On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL.

Slides:

Advertisements

Similar presentations

Meredith Cook Mercer COPHS August,2012. Total Cholesterol HDL Could CVD prediction be improved by also assessing additional lipid-related markers (replacing.

Advertisements

Relationship of LDL-C & LDL-P. Lipoprotein Particles LipoScience 2007 NON-POLAR LIPID CORE Cholesterol Ester Triglyceride POLAR SURFACE COAT Phospholipid.

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Break the Fast: “Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control.

Lipid Disorders and Management in Diabetes

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

Blood samples available from study participants with myocardial infarction and controls by ethnic origin Matthew J McQueen, et al. Lancet 2008; 372:

Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

Women and Cholesterol What You Need to Know. Age: 45 Women and Cholesterol: What You Need to Know HDL: 60 mg/dL and above LDL: Below 100 mg/dL GoodBad.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

Philip J. Barter, et al. Circulation 2011;124:

PPAR  activation & lipid metabolism. Diabetic dyslipidaemia Lipid profiles and hyperinsulinaemia in newly diagnosed type 2 diabetic patients Niskanen.

Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:

Parish S, et al. Eur Heart J 2009 [Epub ahead of print]

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Lipid Profile, Plasma Apolipoproteins, and Risk of.

Date of download: 6/25/2016 Copyright © 2016 American Medical Association. All rights reserved. From: The Colorado Thyroid Disease Prevalence Study Arch.

Severe Hypoglycemia Identifies Vulnerable Patients With Type 2 Diabetes at Risk for Premature Death and All-Site Cancer: The Hong Kong Diabetes Registry.

Should we move from Lipids to Lipoproteins, from Dyslipidemia to Dyslipoproteinemia in future guidelines for CVD?

Fig. 1. Serum total cholesterol (A), LDL cholesterol (B), triglyceride (C) and HDL cholesterol level (D) according to HBsAg status in age group. Total.

HDL cholesterol and cardiovascular risk Epidemiological evidence

Copyright © 2012 American Medical Association. All rights reserved.

Association of blood lipids with AF

Arterioscler Thromb Vasc Biol

HDL cholesterol and cardiovascular risk

FATS- Familial Atherosclerosis Treatment Study

TNT: Baseline and final LDL cholesterol levels

Behavior and Biology: The Basic Sciences for AHA Action

Figure 7 Mendelian randomization of overlapping exposures

TNT Study: Baseline Characteristics of the Patients

Diabetes hazard rates by number of visits with reported statin use.

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report Terry A. Jacobson, MD, Matthew K. Ito,

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Association between highest tertile for homocysteine and mortality

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Franklin SS, et al. Circulation 2009;119:243-50

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Meredith Kilgore, PhD, Paul Muntner, PhD, J

Description of studies for pooled analyses

Hazard ratios for the primary end point by subgroup of achieved LDL cholesterol (adjusted for age, sex, baseline calculated LDL cholesterol, diabetes,

I ;J\;J\ _\_\ -

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Body mass, BMI, plasma lipids, lipoproteins, and glucose homeostasis at baseline, and following placebo and rosuvastatin periods Dmitri Sviridov et al.

Baseline Characteristics According to Sex

Baseline Characteristics, Blood Pressures, and Laboratory Values

Baseline Characteristics of the Subjects*

Rahilly-Tierney CR et al. Circulation 2009;120:1491-7

Jeffrey S. Berger, et al. Circ Cardiovasc Qual Outcomes 2009;2:78-87

Study Flow Diagram Thompson A, et al. JAMA 2008;299:

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.

Clinical Characteristics, Biochemical and Lipid Profiles, and Carotid IMT in 196 Asymptomatic Subjects With Familial Hypercholesterolemia Mireia Junyent,

PROSPER: trial design

TNT diabetes analysis: Baseline and final LDL cholesterol levels

Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.

Adjusted relative risk Adjusted odds ratio

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Correlation between progranulin (dependent variable) and CKD stage adjusted for age and sex, as well as DBP, WHR, triglycerides, HDL cholesterol, LDL cholesterol,

Flow of study participants

Individual lipid measures for high-carbohydrate (n=10) and low-carbohydrate (n=10) ultra-endurance athletes. Individual lipid measures for high-carbohydrate.

LDL-c reductions below 1

Risk of type 2 diabetes as a function of ABCA1 and ABCG1 genotype in CCHS. Hazard ratios were multifactorially adjusted for age, sex, BMI, hypertension,

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Kastelein JJ, et al. Circulation 2008;117: On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL

Individual Relationships Between On-Treatment Levels of LDL Cholesterol, Non-HDL Cholesterol, Apolipoprotein B, or Their Ratios and MCVEs in TNT and IDEAL Kastelein JJ, et al. Circulation 2008;117:3002-9

Direct Pairwise Comparisons of the Relationships With MCVEs for On-Treatment Levels of LDL Cholesterol, Non-HDL Cholesterol, Apolipoprotein B, or Their Ratios in TNT and IDEAL Kastelein JJ, et al. Circulation 2008;117: *Calculated by a Cox proportional hazard model with adjustment for the effects of study, age, and sex. †Calculated as total cholesterol minus HDL cholesterol.

Individual Relationships Between On-Treatment Levels of LDL Cholesterol, Non-HDL Cholesterol, Apolipoprotein B, or Their Ratios and MCVEs in Selected Subgroups of TNT and IDEAL Kastelein JJ, et al. Circulation 2008;117: *Calculated by a Cox proportional hazard model with adjustment for the effects of study, age, and sex. †Calculated as total cholesterol minus HDL cholesterol.

Kastelein JJ, et al. Circulation 2008;117: CLINICAL PERSPECTIVE